With the recovery of Losartan with excessively detected impurities, pharmaceutical companies are considering strategies after recovery measures are completed. Many pharmaceutical companies that did not have a very high market share in the Losartan market are reportedly considering gradually withdrawing from the market after the recovery is completed. It is predicted that the pace of market reorganization will accelerate after the recovery measures are completed.

According to the pharmaceutical industry on the 20th, a large Korean pharmaceutical company A is discussing ways to stop selling the product line after the recovery of Losartan is completed. Company A has five Losartan items, and some or all of